BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 19084911)

  • 1. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.
    Sirica AE
    World J Gastroenterol; 2008 Dec; 14(46):7033-58. PubMed ID: 19084911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
    Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies.
    Sirica AE; Lai GH; Zhang Z
    J Gastroenterol Hepatol; 2001 Apr; 16(4):363-72. PubMed ID: 11357901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours.
    Altimari A; Fiorentino M; Gabusi E; Gruppioni E; Corti B; D'Errico A; Grigioni WF
    Dig Liver Dis; 2003 May; 35(5):332-8. PubMed ID: 12846405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma.
    Terada T; Ashida K; Endo K; Horie S; Maeta H; Matsunaga Y; Takashima K; Ohta T; Kitamura Y
    Histopathology; 1998 Oct; 33(4):325-31. PubMed ID: 9822921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular aspects of cholangiocarcinoma.
    Kiguchi K
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma.
    Jan YY; Yeh TS; Yeh JN; Yang HR; Chen MF
    Ann Surg; 2004 Jul; 240(1):89-94. PubMed ID: 15213623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.
    Radaeva S; Ferreira-Gonzalez A; Sirica AE
    Hepatology; 1999 May; 29(5):1453-62. PubMed ID: 10216129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
    Pellat A; Vaquero J; Fouassier L
    Hepatology; 2018 Feb; 67(2):762-773. PubMed ID: 28671339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
    Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
    Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma.
    Ito Y; Takeda T; Sasaki Y; Sakon M; Yamada T; Ishiguro S; Imaoka S; Tsujimoto M; Higashiyama S; Monden M; Matsuura N
    Pathol Res Pract; 2001; 197(2):95-100. PubMed ID: 11261824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.
    Choi HJ; Kim HJ; Choi JH
    Hepatogastroenterology; 2009; 56(91-92):606-9. PubMed ID: 19621664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
    Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
    Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
    Wu T
    Biochim Biophys Acta; 2005 Jul; 1755(2):135-50. PubMed ID: 15921858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy.
    Sirica AE
    Hepatology; 2005 Jan; 41(1):5-15. PubMed ID: 15690474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
    Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
    BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
    Muthuswamy SK; Gilman M; Brugge JS
    Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.
    Endo K; Yoon BI; Pairojkul C; Demetris AJ; Sirica AE
    Hepatology; 2002 Aug; 36(2):439-50. PubMed ID: 12143054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.